Bioventix plc
(“Bioventix” or
“the Company”)
Director
Dealing
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, announces that
the Company was notified on 26 April
2022 that on 25 April 2022
Bruce Hiscock, Chief Financial Officer of the Company, purchased a
total of 3 ordinary shares of 5 pence
each in the Company (“Ordinary Shares”), at an average price of
3,500 pence per Ordinary Share (the
“Purchase”). The shares were purchased under a dividend
reinvestment plan (DRIP).
Following the Purchase, Bruce
Hiscock has a beneficial interest in 424 Ordinary Shares,
representing approximately 0.01 per cent. of the issued share
capital of the Company.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details.
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
This announcement contains inside
information for the purposes of Article 7 of the Market Abuse
Regulation (EU) 596/2014 as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the company's obligations under
Article 17 of MAR.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
| 1 |
Details of the person
discharging managerial responsibilities / person closely
associated |
| a) |
Name |
Bruce Hiscock |
| 2. |
Reason for the
Notification |
| a) |
Position/status |
Chief Financial Officer |
| b) |
Initial notification/Amendment |
Initial notification |
| 3. |
Details of the
issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor |
| a) |
Name |
Bioventix Plc |
| b) |
LEI |
213800225MHX7LZQY108 |
| 4. |
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted |
| a) |
Description of the Financial
instrument, type of instrument |
Ordinary Shares of 5 pence each |
| Identification code |
GB00B4QVDF07 |
| b) |
Nature of the transaction |
Purchase of Ordinary Shares |
| c) |
Price(s) and volume(s) |
3 Ordinary Shares
3,500 pence |
| d) |
Aggregated
information:
· Aggregated volume
· Price |
Purchase of 3 Ordinary Shares at
3,500 pence each |
| e) |
Date of the transaction |
25 April 2022 |
| f) |
Place of the transaction |
London Stock Exchange, AIM Market
(XLON) |
